Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies

Symposium
Chairs: P. Zatloukal (Prague, Czech Republic), C. Brambilla (Grenoble, France)
Aims: This symposium will give some practical guidelines for treating patients with good performance status, as well as elderly and performance status 2–3 patients.

The role of the EGFR-pathway and angiogenesis in lung cancer: basic considerations E. Brambilla (Grenoble, France)
What specific issues arise in the management of elderly patients with advanced NSCLC? J. Vansteenkiste (Leuven, Belgium)
Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? P. E. Postmus (Amsterdam, The Netherlands)
Second- and third-line therapies: what are the best options? R. M. Huber (Munich, Germany)